Beigene (NASDAQ:ONC) Sets New 52-Week High – What’s Next?

Beigene, Ltd. (NASDAQ:ONC) reached a new 52-week high during trading on Thursday . The stock traded as high as $268.45 and last traded at $259.00, with a volume of 710828 shares traded. The stock had previously closed at $259.70.

Wall Street Analyst Weigh In

Separately, Macquarie lifted their price objective on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research note on Friday.

Beigene Stock Performance

The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $26.60 billion, a P/E ratio of -32.99, a price-to-earnings-growth ratio of 7.73 and a beta of 0.63.

Beigene (NASDAQ:ONC) last released its earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. As a group, equities analysts anticipate that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Insider Transactions at Beigene

In other news, Director Bros. Advisors Lp Baker sold 732,827 shares of Beigene stock in a transaction on Friday, February 28th. The stock was sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the completion of the sale, the director now directly owns 730,642 shares in the company, valued at approximately $189,966,920. This trade represents a 50.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Chan Henry Lee sold 1,202 shares of Beigene stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $258.04, for a total value of $310,164.08. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 790,950 shares of company stock worth $204,616,547. 7.43% of the stock is currently owned by insiders.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.